- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Undervalued based on future growth
Australian Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Clinuvel Pharmaceuticals
Market Cap: AU$540.7m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.77
7D
-6.3%
1Y
-21.4%
EZZ Life Science Holdings
Market Cap: AU$114.2m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.
EZZ
AU$2.42
7D
7.6%
1Y
-15.4%